


RETRACTION NOTE

Open Access



Retraction Note: MNAT1 is overexpressed in colorectal cancer and mediates p53 ubiquitin-degradation to promote colorectal cancer malignance

Shan Zhou^{1,2†}, Jinping Lu^{2†}, Yuejin Li^{1†}, Chan Chen², Yongqiang Cai², Gongjun Tan², Zhengke Peng², Zhenlin Zhang², Zigang Dong³, Tiebang Kang⁴ and Faqing Tang^{1*} 

Retraction Note: *J Exp Clin Cancer Res* 37, 284 (2018)
<https://doi.org/10.1186/s13046-018-0956-3>

The Editor-in-Chief has retracted this article at the request of the authors. After publication, concerns were raised about the data presented in Fig. 8c having been published elsewhere representing different samples [1–5]. The authors checked their data and noticed that inaccurate results were presented in Fig. 1B, 3F and 5E. Further investigation revealed the following additional issues:

- In Fig. 4D, the background of parts of the Flag bands appears completely smooth, as if parts of the image have been removed.
- In Fig. 5E (right panel), there is a noticeable break in the background of the blot, and the two parts are misaligned in the image.

- In Fig. 6C,
 - the image of the bands presented for MNAT1 (LoVo cells) appears highly similar to that in Fig. 2D DLD1 cells;
 - MDM2 and MNAT1 and HSP60 (HEK293T cells) appear highly similar to Fig. 2A MNAT1 and GAPDH (HCT116 cells);
 - p53 (LoVo cells) bands appear highly similar to those presented for MNAT1 in Fig. 6D.
- In Fig. 7A, the GAPDH bands appear highly similar to the HSP70 bands in Fig. 3A-b.

The data reported in this article are therefore unreliable. In addition, the authors were unable to provide a copy of the original Ethics Approval for the animal study upon the Editor's request, which raises further concerns about the integrity of the article.

None of the authors have responded to any correspondence from the editor or publisher about this retraction.

The original article can be found online at <https://doi.org/10.1186/s13046-018-0956-3>.

*Correspondence: qyang@wustl.edu

[†]Shan Zhou, Jinping Lu and Yuejin Li contributed equally to this work.

¹ Department of Clinical Laboratory, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China

Full list of author information is available at the end of the article

Author details

¹Department of Clinical Laboratory, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. ²Department of Clinical Laboratory, Zhuhai Hospital, Jinan University, Zhuhai 519000, Guangdong, China. ³Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912, USA. ⁴State Key Laboratory of Oncology in South China and Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, China.



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 24 December 2021

References

1. Tang F, Wang D, Duan C, et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. *J Biol Chem*. 2009;284(40):27456–66. <https://doi.org/10.1074/jbc.M109.033795>.
2. Huang D, Li Y, Liu N, et al. Identification of novel signaling components in N,N'-Dinitrosopiperazine-mediated metastasis of nasopharyngeal Carcinoma by quantitative phosphoproteomics. *BMC Cancer*. 2014;14:243. <https://doi.org/10.1186/1471-2407-14-243>.
3. Tan G, Tang X, Huang D, Li Y, Liu N, Peng Z, et al. Dinitrosopiperazine-mediated phosphorylated-proteins are involved in nasopharyngeal carcinoma metastasis. *International Journal of Molecular Sciences*. 2014;15:20054–71.
4. Peng Z, Liu N, Huang D, Duan C, Li Y, Tang X, et al. N,N'-dinitrosopiperazine-mediated heat-shock protein 70-2 expression is involved in metastasis of nasopharyngeal carcinoma. *PLoS ONE*. 2013;8(5):e62908. <https://doi.org/10.1371/journal.pone.0062908>.
5. Tang F, Zou F, Peng Z, et al. N,N'-dinitrosopiperazine-mediated ezrin protein phosphorylation via activation of Rho kinase and protein kinase C is involved in metastasis of nasopharyngeal carcinoma 6-10B cells. *J Biol Chem*. 2011;286(42):36956–67. <https://doi.org/10.1074/jbc.M111.259234>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

